PainCeptor Achieves Development Milestones for Innovative Pain Therapeutics Programs
PainCeptor Pharma Corp., a drug discovery and development company focused on novel therapeutic targets for the treatment of chronic and acute pain, announced that it has met its key development milestones and has selected pre-clinical development lead candidates for its two most advanced programs. The performance milestones were part of the Company's $23 M Series A venture funding in March, 2004, and specified a number of scientific and corporate development goals and timelines. As a result of meeting these objectives, the second and final tranche of the Series A financing has been released.
The most notable of these milestones was the selection of pre-clinical lead candidates for each of PainCeptor's two key programs, ASIC 1 and NGF/P75 antagonists. These candidate selections will enable the programs to advance through the pre-clinical toxicology and pharmacokinetics stages and remain on schedule for IND and the commencement of clinical trials in 2006 and early 2007, respectively.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.